To find candidates for novel blood-based biomarkers of AD, plasma proteomics analyses and biochemical validation using the enzyme-linked immunosorbent assay and X-MAP technology are ongoing.
Genetic analyses using next generation sequencing technologies including whole genome sequencing as well as targeted gene panel analyses are underway.